Drug Primer: Nitazenes
By Kevin Shanks, D-ABFT-FT
Over the last several years, the Drug Enforcement Administration (DEA) has moved to ban various newly emerged illicit opioids as Schedule I controlled substances. From 2015-2017, they controlled 19 fentanyl analogs and other opioids. In 2018, the DEA banned any substitutions to the fentanyl core chemical structure and classified them as “fentanyl-related substances”.
![](https://axisfortox.com/wp-content/uploads/2022/06/Nitazenes_FederalLegislation_2015-2017-300x210.jpg)
Waves of Federal Legislation for Opioids
DEA, 2015 – 2017
After this legislation in 2018, compounds that were chemically dissimilar from fentanyl and analogs began to emerge. The major family of non-fentanyl related compounds to emerge is known as the nitazenes, which are based on a benzimidazole chemical structure. This family of opioids was first synthesized in the 1950s in the pharmaceutical industry as potential analgesic and anesthetic medications. The first compound, also the most potent, is etonitazene. Other compounds in this family include butonitazene, flunitazene, isotonitazene, metonitazene, and N-pyrrolidinoetonitazene. Pharmacologically, these compounds are mu opioid receptor agonists, much like morphine, heroin, and fentanyl. In vitro data suggests that these compounds have analgesic potentcies similar to or greater than fentanyl, and because of this potency and potential for respiratory depression, they have never been investigated further or approved for use in medicine.
![](https://axisfortox.com/wp-content/uploads/2022/06/Nitazenes_ChemicalStructure-300x276.jpg)
Chemical Structure of Isotonitazene.
Kevin G. Shanks (2022)
We screen for nitazene compounds by liquid chromatography with quadrupole time of flight mass spectrometry (LC-QToF-MS) and confirm their identity by liquid chromatography with triple quadrupole mass spectrometry (LC-MS/MS) test. Test specifics can be found in the Axis online catalog.
From June 1, 2021 to May 1, 2022, we detected a total of four nitazene compounds (metonitazene, isotonitazene, flunitazene, and N-pyrrolidinoetonitazene) in 128 postmortem toxicology blood samples across eight states (Florida, Illiniois, Indiana, Michigan, Nebraska, Ohio, Texas, and Wisconsin). Fentanyl was most commonly found alongside nitazene compounds, but other substances included 4-ANPP, acetylfentanyl, naloxone, methamphetamine, THC, cocaine/benzoylecgeonine, and morphine.
If you have any questions about these newly emerged nitazene compounds, please reach out to subject matter experts at Axis by email at [email protected].
References
Axis Forensic Toxicology internal data for nitazene analysis. 06/01/2021 – 05/01/2022.
- Published in Drug Classes
Nitazene Analog Panel Coming Soon
Dear Valued Client,
In the spirit of continual improvement, to provide the most relevant panels and tests in the industry, our products are periodically updated as new compounds emerge and older compounds cease to be relevant over the years. It is with that goal in mind that we announce the creation of the 13910: Nitazene Analog Panel. Beginning with orders placed on or after June 27th, 2022, the 13910: Nitazene Analog Panel will include the following compounds:
- Butonitazene
- Etodesnitazene
- Etonitazene
- Flunitazene
- Isotodesnitazene
- Isotonitazene
- Metodesnitazene
- Metonitazene
- N-Pyrrolidino Etonitazene
- Protonitazene
In addition, as part of this change, these compounds will be removed from the 13710: Novel Emerging Compounds Panel. All of these compounds will still be included as part of the 70510: Comprehensive Panel, Blood with Analyte Assurance™.
You can always find the most recent publication for our panel offerings on our Test Catalog, found at www.axisfortox.com.
For specific questions regarding our tests or tests not found on our Test Catalog, please contact our Lab Client Support Team at [email protected].
We look forward to serving you.
Sincerely,
Matt Zollman
Director of Operations & Product Management
- Published in Announcements
Drug Primer: Mitragynine (Kratom)
By Kevin Shanks, D-ABFT-FT
Mitragyna speciosa is a tree or shrub that grows in southeast Asia, particularly Thailand and Malaysia. The plant is locally known as kratom or biak-biak. It exists in the Rubiaceae family of plants, which includes the genera Coffea or caffeine-containing plants, with the most-widely known species being Coffea arabica and Coffea canephora (coffee plants). In regions of Asia, the plant has been used by either chewing the leaves or brewing them into a liquid beverage such as a tea. The leaves can also be pulverized and fashioned into a powder and then smoked or consumed orally in a capsule.
![](https://axisfortox.com/wp-content/uploads/2022/05/MitragyninePlant-300x200.jpg)
Mitragyna speciosa
Image by Ahmad Fuad Morad (CC BY-SA 2.0)
Mitragyna contains the alkaloids, mitragynine and 7-hydroxymitragynine. Approximately 60% of the plant’s alkaloid content is mitragynine and 7-hydroxymitragynine makes up about 2% of the overall alkaloid content. In lower dosages, the alkaloids produce stimulant-type effects, but at larger dosages, both compounds function as mu opioid receptor agonists. Mitragynine is considered to be approximately 13 times more potent than morphine as an analgesic, but 7-hydroxymitragynine is considered to be approximately 4 times more potent than mitragynine. 7-hydroxymitragynine is also a product of mitragynine biotransformation in the human body, thus mitragynine can be considered a prodrug for 7-hydroxymitragine. The alkaloids have also been shown to have other effects such as the blocking of serotonergic receptors and inhibition of CYP1A2, CYP2D6, and CYP3A4 enzymes.
![](https://axisfortox.com/wp-content/uploads/2022/05/Mitragynine_ChemicalStructure-193x300.jpg)
Chemical structures of Mitragynine and 7-hydroxymitragynine
Structure drawn by Kevin G. Shanks (2022)
An interesting pharmacological characteristic of mitragynine and 7-hydroxymitragynine is that when binding to opioid receptors, they exhibit biased agonism. Normally, when an opioid binds to an opioid receptor, the β-arrestin pathway is initiated – the β-arrestin pathway is responsible for most of the respiratory depression and sedation observed in opioid use and overdose. There exists evidence that shows mitragynine and 7-hydroxymitragynine do not initiate this pathway.
The United States Federal government moved to control mitragynine and 7-hydroxymitragynine as Schedule I controlled substances in 2016-2018, but backed off the legislation after public comment on the matter. They remain uncontrolled at the Federal level, but some states have passed legislation making them controlled substances in their locale.
Most forensic toxicology laboratories include only mitragynine in the scope of their testing and do not include the 7-hydroxymitragynine alkaloid/metabolite. Typical detection limits for the compound are 5-20 ng/mL in blood. At Axis Forensic Toxicology, mitragynine is included in the Comprehensive Panel (order code 70510) and/or as a directed confirmation test for mitragynine (order code 42090). Specific information about our testing can be found in the online test catalog.
Experts at Axis, alongside the Coconino County (Arizona) Medical Examiner’s Office, recently published a manuscript in the Journal of Analytical Toxicology titled “Two Single-Drug Fatal Intoxications by Mitragynine”. There have been many mitragynine-associated or related intoxications and fatalities reported over the last several years, but most have involved multiple drugs including other central nervous system depressants such as opioids, benzodiazepines, and ethanol. Sole intoxications with mitragynine leading to fatality are rare. In the published article, an analytical method for the detection of mitragynine by liquid chromatography with triple quadrupole mass spectrometry (LC-MS/MS) is detailed as well as presentation of two cases where mitragynine was certified as the single agent in the cause of death of an individual. To request a copy of this new manuscript, please contact us at [email protected].
References
Opioids. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 271-291. (2017).
Mitragynine. Disposition of Toxic Drugs and Chemicals in Man. Twelfth Edition. Randall C. Baselt. Biomedical Publications. Pages 1414-1415. (2020).
“Two Single-Drug Fatal Intoxications by Mitragynine” (2022) G.S. Behonick, C. Vu, L. Czarnecki, M. El-Ters, K. Shanks. J Anal Tox, DOI: https://doi.org/10/1093/jat/bkac016
- Published in Drug Classes
Drug Primer: 4-ANPP
By Kevin Shanks, D-ABFT-FT
This post has been updated since its original posting Apr 7, 2022.
The presence of fentanyl in the street drug supply has rapidly exploded throughout the United States since approximately 2014. Drug overdose deaths have increased as well over the last several years and topped 100,000 deaths in the USA in 2021, with the major driving factor being fentanyl.
![](https://axisfortox.com/wp-content/uploads/2022/04/4ANPP_FentanylTrendsGraph.jpg)
Fentanyl Trends. DEA Annual Report, 2020. NFLIS.
We discussed fentanyl in a previous blog post, but briefly, fentanyl is a mu opioid receptor agonist and is metabolized in the human body by the cytochrome P450 enzyme system, primarily CYP3A4, into various products. It can be dealkylated, hydroxylated, methylated, and hydrolyzed.
In the modern forensic toxicology laboratory, we monitor for the presence of unchanged fentanyl, alongside its primary metabolite, norfentanyl, in blood and urine. But, over the last several years, laboratories have added a third substance to their scope of analysis for fentanyl – 4-ANPP.
![](https://axisfortox.com/wp-content/uploads/2022/04/4ANPP_ChemicalStructure-300x248.jpg)
Chemical structure of 4-ANPP
Drawn by Kevin G. Shanks (2022)
4-ANPP, also known as N-phenyl-1-(2-phenylethyl)-4-piperidinamine or despropionyl fentanyl, is formed via amide hydrolysis. It is a minor metabolite of fentanyl, but it is also a precursor or starting material used in the synthesis of illicitly manufactured fentanyl and various related fentanyl analogs. 4-ANPP is reacted with propionyl anhydride to form fentanyl or some other reagent to form a related fentanyl analog such as acetylfentanyl (acetic anhydride) or cyclopropylfentanyl (cyclopropane carbonyl chloride).
Pharmacologically, 4-ANPP is inactive – it does not produce any specific effect on the body. Ultimately, its presence is merely a marker for fentanyl use or exposure. Detection of this substance in the body is highly dependent on the dose and purity of the product consumed by the individual. The toxicology alone cannot determine if 4-ANPP is present due to metabolism or if it was ingested by using an impure illicit product. There is consensus among pathologists and medical examiners to not include 4-ANPP in cause of death because of its pharmacological inactivity.
As of January 22, 2024, Axis Forensic Toxicology screens for the presence of 4-ANPP in our Comprehensive Panel with Analyte Assurance™ and reflexively confirms it with our Fentanyl & Metabolites Panel (order code 40410), which is completed by liquid chromatography with triple quadrupole mass spectrometry (LC-MS/MS). The reporting limit is 0.1 ng/mL and the substance is reported as qualitatively positive or negative.
If you have any questions regarding the presence or absence of 4-ANPP or its role in your toxicology casework, please reach out to Axis’ subject matter experts at [email protected].
References
Fentanyl. Disposition of Toxic Drugs and Chemicals in Man. Twelfth Edition. Randall C. Baselt. Biomedical Publications. Pages 844-847. (2020).
Opioids. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 271-291 (2017).
2020 Annual Drug Report. National Forensic Laboratory Information System (NFLIS). Drug Enforcement Administration. Springfield, VA. NFLIS-Drug 2020 Annual Report (usdoj.gov). (Accessed March 20, 2022).
Labroo, R.B., Paine, M.F., Thummel, K.E., Kharasch, E.D. (1997) Fentanyl Metabolism by Human Hepatic and Intestinal Cytochrome P450 3A4: Implications for Interindividual Variability in Disposition, Efficacy, and Drug Interactions. Drug Metabolism and Disposition, 25: 9. 1072-1080.
Drug Primer: Fentanyl (2021). Axis Forensic Toxicology Blog. Drug Primer: Fentanyl – Axis Forensic Toxicology (axisfortox.com).
- Published in Drug Classes
Pharmacodynamics
By Kevin Shanks, D-ABFT-FT
Pharmacodynamics (PD) is the study of the effect of substances on the body. The word is derived from Greek – Pharmakon and dynamikos which means “force” or “power”. PD includes concepts such as receptor affinity, receptor activity, and potency.
![](https://axisfortox.com/wp-content/uploads/2022/02/Pharmacodynamics.jpg)
“Whelp” by NoelMichelle. Licensed under CC BY-SA 4.0.
Receptor affinity is the measure of how well a substance binds to a receptor. As an example, let’s look at the opioids, morphine and fentanyl. Both substances bind to the mu (µ) opioid receptor. Morphine binds to the receptor with an affinity (Ki) equal to 1.8 nM, whereas fentanyl binds to the receptor with an affinity (Ki) equal to 0.39 nM. This essentially means that fentanyl has a 4-5 stronger hold at the receptor than morphine does.
Once a substance binds to a receptor, it will produce a response or effect. A substance can bind to the receptor a produce an effect – this is called agonism. A substance can also bind to the receptor and block a response from occurring – this is called antagonism. A drug such as morphine or fentanyl binds to mu opioid receptors and acts as an agonist – it produces analgesia and central nervous system depression. Naloxone, on the other hand, is a receptor antagonist as it binds to mu opioid receptors and does not produce a biological response – it blocks other opioids from binding to the same receptors.
Potency refers to the amount of a substance that is needed to produce a desired effect. To compare drug potencies, we look at the EC50, or the concentration of drug at which 50% of the maximum effect is achieved. When two substances are tested in the same person, the drug with the lower EC50 would be considered more potent. A lesser amount of a more potent drug is needed to achieve the same effect as a less potent drug.
Within the study of the pharmacodynamics of drugs, we are also concerned with the route of administration, onset of action, and duration of action.
The route of administration is the path by which a substance is taken into the body. Common routes of administration include oral (by mouth), dermal absorption, mouth inhalation, nasal inhalation, nasal insufflation, smoking, vaping, intravenous injection, intramuscular injection, intrathecal injection, sublingual absorption, buccal absorption, and rectal absorption. Tablets such as Xanax (alprazolam) and Vicodin (hydrocodone) are to be consumed orally. Cocaine can be nasally insufflated or snorted. Heroin may be injected intravenously. Methamphetamine may be smoked. Nicotine can be vaped.
The onset of action of a drug is the amount of time it takes for a drug’s effects to occur after administration. The onset is dependent on the route of administration, but there are other factors including drug formulation, dosage, and the individual consuming the substance. Substances that are orally consumed typically have an onset of action 30-90 minutes and those substances that are smoked or inhaled have onset of action typically within minutes. Substances that are injected directing into the blood stream have effects that occur within seconds to minutes of administration. As an example, when someone smokes or vapes cannabis, the effects normally occur within minutes, but when someone consumes a THC-infused edible foodstuff by mouth, the onset of action is normally 30-90 minutes after ingestion.
The duration of action of a drug is the length of time that a substance is effective or how long effects are felt. As an example of duration, morphine’s effects are typically felt for 4-5 hours after administration, while fentanyl’s effects are felt for 1-2 hours after use. As with onset of action, the duration of action can also be influenced by route of administration and formulation of drug used. Substances such as Oxycontin (extended release oxycodone) will have a duration approximately 12 hours.
The branch of pharmacology known as pharmacokinetics can help to answer questions such as ‘Are drugs involved in the incident?’ or ‘How much substance did a living individual consume?’ or ‘When was the substance taken?’, but the knowledge of pharmacodynamics can help to answer questions such as ‘During the incident, was an individual impaired?’ or ‘Was the person suffering from toxic drug effects?’ or “Did this substance play a role in the death of the individual?’.
If you have any questions or concerns regarding the role of pharmacodynamics in your toxicology case, please reach out to our Axis Forensic Toxicology subject matter experts at [email protected].
References
Guidelines for the Interpretation of Analytical Toxicology Results. Disposition of Toxic Drugs and Chemicals in Man. Twelfth Edition. Randall C. Baselt. Biomedical Publications. Pages xxx-xlii. (2020).
Pharmacokinetics and Pharmacodynamics. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. American Association for Clinical Chemistry (AACC). 2017. 77-93.
Introduction to Forensic Toxicology. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 1-12. (2008).
Postmortem Toxicology. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 191-218. (2008).
Postmortem Forensic Toxicology. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 3-14. (2017).
- Published in General
Reference Ranges
By Kevin Shanks, D-ABFT-FT
Many forensic toxicology tests are qualitative and provide a positive-negative or present-not detected result. The interpretation of those results is relatively simple. A substance is there or it is not. But, a quantitative test with a numerical result must be put into context of the case to aid in determining its overall meaning. Is the concentration of drug measured significant to the investigation or is it an incidental finding? Forensic toxicologists do this by compiling reference ranges, or sets of blood, serum, or plasma drug or metabolite concentrations which are used as a baseline for interpretation of results.
A therapeutic blood concentration is a concentration or level of drug or its active metabolite which is present in the blood, serum, or plasma following a therapeutically effective dosage. Most therapeutic ranges originate from data amassed during pharmaceutical medication clinical trials or controlled dosing studies. More often than not, the individuals tested to determine a therapeutic blood range consist of a healthy, non-disease stricken population. A toxic blood concentration is a concentration or level of drug or its active metabolite present in the blood, serum, or plasma that is associated with serious adverse or toxic symptoms. A lethal blood concentration is an amount of drug or its active metabolite present in the blood, serum, or plasma that has been reported to cause fatality, or is so far above reported therapeutic or toxic concentrations, that one may judge it might cause fatality.
![](https://axisfortox.com/wp-content/uploads/2022/01/Test-Tubes-and-Other-Recipients-in-Chemistry-Lab-by-Horia-Varlan-200x300.jpg)
Test tubes and other recipients in chemistry lab by Horia Varlan (CC BY 2.0)
Any value given for a therapeutic, toxic, or lethal blood concentration is not considered absolute, but is to be used as a frame of reference or guideline in evaluating a specific case in its context. Blood concentrations can be affected by dose of the substance used, route of administration, drug absorption differences, age and sex of the individual, potential tolerance to the substance, underlying pathology or observed disease states, postmortem redistribution (PMR), substance protein binding, and the accumulation of active metabolites.
Some substances have distinct therapeutic, toxic, and lethal blood reference ranges. This can be shown by looking at acetaminophen (Tylenol). Acetaminophen’s therapeutic reference range is 10-30 mcg/mL while it’s toxic and lethal reference ranges are greater than 150 mcg/mL. As you can see, there is a definite difference observed in the reference ranges.
On the other hand, some substances have overlapping therapeutic, toxic, and lethal blood reference ranges. The reported therapeutic reference range for fentanyl in blood is 1-3 ng/mL. But toxicity may occur at blood concentrations lower than 3 ng/mL. People using fentanyl as a therapeutic medication under the supervision of a physician may also regularly have blood concentration exceeding 3 ng/mL. Another example of this overlap in therapeutic and toxic/lethal ranges is methadone. Acute oral therapeutic dosing of methadone in treatment settings has resulted in blood concentrations 75-860 ng/mL and chronic oral dosing of methadone in medical treatment settings has led to blood concentrations 570-1,006 ng/mL. But, blood concentrations found in the postmortem blood of people who have died from methadone toxicity were 20-5,300 ng/mL.
There is no one size fits all type of reference range for forensic toxicology testing – the interpretation hinges on the context and circumstances of the case. Axis Forensic Toxicology understands that one should never practice toxicology strictly by the numbers and we are able to help with interpretation of the relevant toxicology in your casework.
Axis is making changes to its final toxicology reports to align with and provide a single source of values for the reported reference ranges. If you have any questions or concerns regarding a substance’s reference range or its role in your medical-legal death investigation, please reach out to our subject matter experts at [email protected].
References
Disposition of Toxic Drugs and Chemicals in Man. Twelfth Edition. Randall C. Baselt. Biomedical Publications. (2020).
Pharmacokinetics and Pharmacodynamics. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. American Association for Clinical Chemistry (AACC). 2017. 77-93.
Introduction to Forensic Toxicology. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 1-12. (2008).
Postmortem Toxicology. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 191-218. (2008).
Postmortem Forensic Toxicology. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 3-14. (2017).
- Published in General
Shipping Best Practices
By Matt Zollman, Director of Operations and Product Management
From time to time, circumstances such as weather or pandemics can cause shipment delays. Here are some Best Practices to keep in mind as you prepare and track your packages:
Submissions:
- Submit smaller, more frequent shipments. If delays do occur, smaller, more frequent shipments minimize the overall impact to your cases.
- Review your Axis Case Management Portal. Cases are posted to your Case Management Portal once they are logged into our system, where you have visibility into when they are received.
- Record your outbound tracking numbers. We’re not able to see all of them in the system and recording them on your end aids in troubleshooting delays.
Supplies:
- You should receive outbound notification. You should receive an e-mail notification when outbound supplies are ready to be sent. If you do not receive a notification in a timely manner after supplies are requested, please notify Axis.
- Please reach out if you do not receive your order. You should receive your shipment in a timely manner. If you do not, please notify Axis for quick resolution.
Axis is committed to providing the same level of service to which you have become accustomed and, to that end, will continue to communicate any additional delays. As always, if you have any questions about your cases or supplies, please reach out to [email protected] or [email protected].
We look forward to serving you.
- Published in General
Pharmacokinetics
By Kevin Shanks, D-ABFT-FT
Pharmacokinetics (PK) is the study of what the body does to a substance. The word is derived from Greek – Pharmakon which means “drug” and kinetikos which means “moving”. PK consists of four areas – absorption, distribution, metabolism, and excretion. This is also known as ADME.
![](https://axisfortox.com/wp-content/uploads/2022/01/EquipmentInTheDMPKLab-300x202.jpg)
Instrumentation in the Drug Metabolism and Pharmacokinetics Lab “Equipment used in the DMPK Lab” by NIH-NCATS is licensed under CC PDM 1.0.
Absorption (A) is the process by which substances enter the bloodstream. Substances can enter the bloodstream through a wide variety of routes, including oral (by mouth), inhalation (lungs), intravenous (injected into a vein), intramuscular (injected into muscle), rectal (suppository), oral mucosa (under the tongue), intrathecal (spinal fluid), dermal (skin), ocular (eye), and intranasal (nose).
Distribution (D) refers to the transfer of a substance form one part of the body to another. When discussing PK, this usually refers to the movement of substance from the blood into the tissues of the body (liver, heart, kidney, brain, muscle, and fat). Some factors that influence distribution are lipophilicity, pH, and plasma protein binding.
![](https://axisfortox.com/wp-content/uploads/2022/01/Heroin-Metabolism.jpg)
Metabolism of Heroin (Diacetylmorphine) Chemical structures drawn by Kevin G. Shanks (2018)
Metabolism (M) is the process by which the substance is altered to facilitate the removal of it from the body. Most metabolism occurs in the liver, but it can also occur in the kidneys, lung, gastrointestinal tract, and blood. Examples of metabolism include deacetylation (heroin to 6-acetylmorphine to morphine), nitro reduction (clonazepam to 7-aminoclonazepam), N-dealkylation (amitriptyline to nortriptyline), deamination (chlordiazepoxide to demoxepam to nordiazepam), and ester hydrolysis (cocaine to benzoylecgonine), as well as glucuronidation (oxazepam to oxazepam glucuronide), sulfate formation (morphine to morphine sulfate), and glycine conjugation (salicylate to salicyluric acid)
Excretion (E) is the final removal of the substance or by products from the body. Excretion is most commonly done via the liver and kidneys, but can occur via the lungs, breast milk, feces, sweat, sebum, and semen.
PK can help answer questions such as ‘Are drugs involved in this incident?’, ‘How much substance did a living individual consume?’, or ‘When was a substance taken by an individual?’.
The larger question at hand in many cases regarding impairment, drug toxicity, or a substance’s role in cause of death involves a related area of pharmacology called pharmacodynamics (PD), which will be explored in a later blog post.
If you have any questions or concerns regarding the role of pharmacokinetics in your toxicology case, please reach out to our Axis Forensic Toxicology subject matter experts at [email protected].
References
Guidelines for the Interpretation of Analytical Toxicology Results. Disposition of Toxic Drugs and Chemicals in Man. Twelfth Edition. Randall C. Baselt. Biomedical Publications. Pages xxx-xlii. (2020).
Pharmacokinetics and Pharmacodynamics. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. American Association for Clinical Chemistry (AACC). 2017. 77-93.
Introduction to Forensic Toxicology. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 1-12. (2008).
Postmortem Toxicology. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 191-218. (2008).
Postmortem Forensic Toxicology. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 3-14. (2017).
Alcohol, Drugs, and Driving. Clarke’s Analytical Forensic Toxicology. Sue Jickells and Adam Negrusz. Pharmaceutical Press. Pages 299-322. (2008).
Human Performance Toxicology. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 15-30. (2017).
- Published in General
Drug Primer: Fentanyl
Fentanyl was originally synthesized by Paul Janssen in 1960 and was initially marketed as Sublimaze® and used as a general anesthetic. In the mid-1990s, fentanyl was introduced to the pharmaceutical market as a transdermal patch and marketed as Duragesic®. The Actiq® transmucosal lollipop and Fentora® buccal tablet were introduced in the 2000s. Historically, fentanyl has been used to treat breakthrough pain and is used in pre-operation procedures as an analgesic and anesthetic. Fentanyl is considered a Schedule II controlled substance in the USA and is only available via physician’s prescription as a pharmaceutical.
![](https://axisfortox.com/wp-content/uploads/2021/05/Fentanyl_01_2021-300x159.jpg)
Chemical structure of Fentanyl
Structure drawn by Kevin G. Shanks (2021)
The substance is a mu (µ) opioid agonist and is considered to be 100-200 times more potent than morphine and up to 40 times more potent that diacetylmorphine (heroin) as an analgesic. Fentanyl’s blood elimination half-life is 3-30 hours but is dependent on the route of administration. Its volume of distribution is 2.5-3.5 L/kg. Fentanyl is biotransformed to its primary metabolite, norfentanyl, via the cytochrome P450 enzyme system. Other metabolites include hydroxyfentanyl, hydroxynorfentanyl, and despropionylfentanyl (4-ANPP). Effects of fentanyl use are analgesia, drowsiness, dizziness, incoordination, weakness, and lethargy. Adverse effects in overdose are central nervous system depression, respiratory depression, seizure, hypotension, apnea, hypoxia, and death.
![](https://axisfortox.com/wp-content/uploads/2021/05/Fentanyl_02_2021.jpg)
Metabolism of Fentanyl to Norfentanyl
Drawn by Kevin G. Shanks (2021)
Fentanyl appeared on the illicit drug market in the USA in the 1970s. Illicitly manufactured fentanyl (of a non-pharmaceutical origin) typically originates from China and other Asian countries and can also be ordered off the “dark web” – internet sites designed to peddle illicit materials. As fentanyl has become a common adulterant in street heroin, the Drug Enforcement Administration (DEA) has reported an explosion of fentanyl-related drug seizures in recent years. From 2010 to 2019, fentanyl detections increased by 16,990%. Since 2019, the numbers have grown larger.
![](https://axisfortox.com/wp-content/uploads/2021/05/Fentanyl_03_2021.jpg)
Regional trends in fentanyl 2001 – 2019.
NFLIS Annual Drug Report, 2019.
The modern forensic toxicology laboratory monitors both fentanyl and norfentanyl in blood and urine specimens. Typical detection limits for both parent drug and metabolite in biological matrices are typically 0.1 – 0.5 ng/mL. The current scope of testing and reporting limits offered by Axis Forensic Toxicology can be found in the online test catalog https://axisfortox.com/test_catalog/.
References
Fentanyl. Disposition of Toxic Drugs and Chemicals in Man. Twelfth Edition. Randall C. Baselt. Biomedical Publications. Pages 844-847. (2020).
Opioids. Principles of Forensic Toxicology. Fourth Edition. Barry Levine. AACC, Inc. Pages 271-291 (2017).
National Forensic Laboratory Information System (NFLIS). Drug Enforcement Administration. Springfield, VA. https://www.deadiversion.usdoj.gov/nflis/index.html. (accessed April 15, 2021).
NFLIS Brief: Fentanyl, 2001-2015. U.S. Department of Justice, Drug Enforcement Administration – National Forensic Laboratory Information System (NFLIS). Springfield, VA. (2017).
- Published in Drug Classes
Novel Emerging Compounds Panel Update
By Matt Zollman, Director of Operations and Product Management
In the spirit of continual improvement, to provide the most relevant panels and tests in the industry, our products are periodically updated as new compounds emerge and older compounds cease to be relevant over the years. It is with that goal in mind that we announce an update to our 13710: Novel Emerging Compounds Panel. Beginning with orders placed on or after November 8th, 2021, the 13710: Novel Emerging Compounds Panel will include the following compounds, in addition to those already in the panel:
- AP-237
- Butonitazene
- Etonitazene
- Flunitazene
- Fluorofentanyl
Attached you will find our most recent publications for our 13710: Novel Emerging Compounds Panel (Panel Specifications). Additionally, you can always find the most recent publication for our panel offerings on our Test Catalog, found at www.axisfortox.com.
For specific questions regarding our tests or tests not found on our Test Catalog, please contact our Lab Client Support Team at [email protected].
We look forward to serving you.
- Published in Announcements